Categories: LATEST NEWS

Collaboration Invite in Biologics and Bioprocessing

Invitation to Collaborate on innovation in Biologics and Bioprocessing – Following yesterday’s announcement by the UK Government to invest an additional ֲ£146m into medicines research, it is clear there has never been a more exciting time for companies to secure funding to de-risk innovative therapies and technologies. However, for a business, it can be difficult to know where to start, and the wealth of information available can be difficult to digest.

The Centre for Process Innovation’s (CPI) National Biologics Manufacturing Centre, based at central park in Darlington, was established to support the growth of the UK biologics industry. The Centre combines state-of-the-art facilities and technical expertise to help companies develop, prove and commercialise the next-generation of biologics. CPI is supporting the commercialisation of research by promoting collaboration with industry across the supply chain, from research through to manufacture and clinic. The Centre is helping companies to commercialise ideas, getting them to market faster with minimal risk, enabling the delivery of innovative manufacturing solutions to accelerate the growth of new and emerging biologic medicines.

Currently CPI is actively looking to collaborate with and support businesses interested in applying for funding to support innovation in biologics and bioprocessing. CPI’s National Biologics Manufacturing Centre has much to offer and we invite potential collaborators to submit project proposals across several areas as follows.

Accessing Cutting Edge Infrastructure and Technical Expertise

CPI has a proven track record of securing and delivering collaborative projects, and can help with all aspects of the development process including selecting the most appropriate call, writing your application, restrictions and regulations right through to delivery and follow on projects. As part of the High Value Manufacturing Catapult, we have a core remit to drive manufacturing technology innovation to benefit UK business and drive UK competitiveness.

CPI has over ֲ£100m of open access development and prototyping facilities. We have helped over 1,000 companies to develop new products and processes and completed over 800 projects worth over ֲ£400m. Within the National Biologics Manufacturing Centre, CPI has secured and is executing 54 projects (completed or in progress), with a total combined value of approximately ֲ£35m for commercial and collaborative projects.

Current Immediate Funding Opportunities

The Biomedical Catalyst aims to develop innovative solutions to health and care challenges. Areas of interest include stratified healthcare (both therapy and diagnostic components), regenerative medicine, diagnostics and enabling medical technologies and devices. Projects can range from 1-3 years in duration, and could be worth ֲ£250k-ֲ£4m.

The Medicines Manufacturing Challenge is the first ֲ£15m investment from a total investment of ֲ£146m into healthcare challenges, and aims to improve the manufacture of novel medicines. Areas of interest include ATMPs, natural product medicines, nucleic acid-based drugs, prophylactic vaccines, protein/peptide biopharmaceuticals, small molecule pharmaceuticals, and virus/phage therapeutics. Projects can be up to 3 years in duration, and could be worth up to ֲ£2m.

If you would be interested in hearing more about the opportunities that are listed above or have a project in mind that could benefit from our collaboration, please contact Mark Bustard, Business Development Director, Biologics, CPI.

Liat

Comments are closed.

Recent Posts

BeyondTrust Acquires Entitle, Strengthening Privileged Identity Security Platform with Paradigm Shifting Just-in-Time Access and Identity Governance

Entitle is a pioneering privilege management solution that discovers, manages, and automates just-in-time (JIT) access and modern identity governance and…

3 weeks ago

Samtec Introduces SIBORG Tool to Speed Component Launch Designs

Available freely to Samtec customers under NDA, SIBORG (Signal Integrity Breakout Region Guru) works with Ansys HFSS 3D Layout to…

3 weeks ago

Accelerating Mass Business AI Adoption: NeuReality Launches Developer Portal for NR1 Inference Platform, Expanding Affordable AI Access

Entire NR1 system purpose-built for a more affordable AI infrastructure allowing for faster deployment; furthering AI’s reach into more parts…

3 weeks ago

Dot Compliance Raises a $17.5 Million Up-Round in Series B Extension Funding to Advance New Category of AI-driven Compliance

Following rapid growth in its customer base to over 400, funding will fuel further AI development and create a hybrid…

3 weeks ago

Tektronix and recently acquired EA Elektro-Automatik now offer expanded power portfolio for engineers who are electrifying our world

The addition of EA’s high-efficiency regenerative power supplies greatly expands Tektronix’s trusted offering Tektronix, Inc, a leading provider in test…

3 weeks ago

Melexis unveils fully integrated inductive switch

Melexis reveals its groundbreaking Induxis® switch, the MLX92442. Contactless, magnet-free, and strayfield immune, this monolithic solution directly detects conductive targets.…

3 weeks ago